title: JCL roundtable: Apolipoproteins as causative elements in vascular disease.
abstract: In clinical lipidology, we have focused our major efforts in defining risk status and specifying the targets of therapy by using the cholesterol content of the lipoproteins. However, we now know that these measures are variable and that they may not reveal all the valuable information that can be used to treat our patients. The amount of cholesterol in each lipoprotein can be quite different in different patients. The number of particles containing apolipoprotein B (apoB) can be abnormally high with a value for low-density lipoprotein cholesterol, which is within our guidelines. Furthermore, the content of apoC3 in apoB-containing lipoproteins can predict risk without a close association with triglycerides or cholesterol. The genome-wide association studies and studies in special families with known genetic polymorphisms have been particularly revealing relationships between these vascular risk.
authors.affiliation: Emeritus College, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: wbrow925@bellsouth.net.
authors.forename: W Virgil
authors.initials: WV
authors.lastname: Brown
authors.affiliation: Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
authors.forename: Frank M
authors.initials: FM
authors.lastname: Sacks
authors.affiliation: Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada.
authors.forename: Allan D
authors.initials: AD
authors.lastname: Sniderman
mesh_terms: D001053:Apolipoproteins / Q000378:metabolism*; D055106:Genome-Wide Association Study; D006801:Humans; D012307:Risk Factors; D014652:Vascular Diseases / Q000453:epidemiology / Q000235:genetics / Q000378:metabolism*
chemical_list: D001053:Apolipoproteins
keywords: ApoB; ApoC3; Apolipoproteins; Cholesterol; Vascular disease